Julie Fitzgerald to Immunotherapy
This is a "connection" page, showing publications Julie Fitzgerald has written about Immunotherapy.
Connection Strength
0.384
-
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021 07; 18(7):435-453.
Score: 0.106
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020 12; 8(2).
Score: 0.104
-
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016 06; 6(6):664-79.
Score: 0.075
-
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013 Jun 27; 121(26):5154-7.
Score: 0.062
-
Pediatric Sepsis: Evolving Subphenotypes, Overlap Syndromes, and the Path to Precision Therapies. Clin Chest Med. 2026 Mar; 47(1):57-66.
Score: 0.037